SCHEMBL3557070

SCHEMBL3557070

Cc1nc2cccc(C(=O)O)c2nc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.68
PDE10A Q9Y233 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
DHODH Q02127 1/20 0.44
CYP1A2 P05177 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA12 O43570 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30380388 1.00 ALDH1A1 (0.68) ALDH1A1PDE10AKMT2AMEN1TDP1
SCHEMBL68995 0.86 ALDH1A1 (0.88) ALDH1A1KMT2ATDP1DHODHCYP1A2
SCHEMBL30548734 0.86 ALDH1A1 (0.88) ALDH1A1KMT2ATDP1DHODHCYP1A2
SCHEMBL2606618 0.84 PARP1 (0.56) ALDH1A1
SCHEMBL5448034 0.84 ALDH1A1 (0.71) ALDH1A1KMT2AMEN1TDP1DHODH
SCHEMBL7566595 0.82 ALDH1A1 (0.69) ALDH1A1KMT2ADHODHCYP1A2MAPT
SCHEMBL5457153 0.82 ALDH1A1 (0.69) ALDH1A1KMT2AMEN1TDP1DHODH
SCHEMBL19971558 0.81 ALDH1A1 (0.73) ALDH1A1KMT2ADHODHCYP1A2MAPT
Phenazine-1-Carboxylic Acid SCHEMBL27752237 0.81 ALDH1A1 (0.93) ALDH1A1KMT2AMEN1DHODHCYP1A2
Phenazine-1-Carboxylic Acid SCHEMBL122864 0.81 ALDH1A1 (1.00) ALDH1A1KMT2AMEN1DHODHCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US claimed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US claimed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed
WO-2022008896-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS. GOLDING, LOUISE (GB) 2022-01-13 WO disclosed
CN-101203518-B Fluorene derivative, composition containing the same and use thereof AVENTIS PHARMA SA 2013-07-24 CN disclosed
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
CN-101203518-A Novel fluorene derivatives, compositions containing same and uses thereof AVENTIS PHARMA SA (FR) 2008-06-18 CN disclosed
EP-1539747-B1 N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2006-11-02 EP disclosed
US-20060040937-A1 N-aroyl cyclic amines as orexin receptor antagonists GLAXO GROUP LIMITED (GB) 2006-02-23 US disclosed
EP-1539747-A1 N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-06-15 EP disclosed
WO-2004026866-A1 N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS CBR3, GBA3, TECR ALDH1A1 2476/4885PDE10A 4221/4885KMT2A 4173/4885
US-20060040937-A1 N-aroyl cyclic amines as orexin receptor antagonists HCRTR2, HCRTR1, NTSR2 ALDH1A1 1698/4885PDE10A 707/4885KMT2A 776/4885
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 ALDH1A1 3050/4885PDE10A 3306/4885KMT2A 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.